Review



human lrg1 ab  (Assaypro)


Bioz Verified Symbol Assaypro is a verified supplier
Bioz Manufacturer Symbol Assaypro manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Assaypro human lrg1 ab
    Plasma leucine-rich alpha-2 glycoprotein 1 <t>(LRG1)</t> levels in lupus nephritis (LN) patients and its correlation to indicators. a Plasma LRG1 levels in LN patients and healthy controls. b Differences in plasma concentrations of LRG1 between different patients with different CKD grades. c Plasma levels of LRG1 are positively correlated with serum creatinine (γ = 0.294, P < 0.01). d , e Differences in plasma concentrations of LRG1 between different patients with different SLE activity grade (SLEDAI) and renal SLEDAI (rSLEDAI). f Differences in plasma concentrations of LRG1 between different patients with other different clinical and pathological indicators, 1 and 2 are representative < and ≥ median: 29.0 years for age, 5.0 AI score, 4.0 CI score, 0.4 for complement 3 (C3); female and male for gender; < and ≥ 20 for SLEDAI;<20 and ≥ 20 mm/h for erythrocyte sedimentation rate (ESR); − and + for hematuria, heavy proteinuria, pyuria, casts, double track sign, wireloop sign, endothelial cells hyperplasia and fibrosis; light and heavy for inflammatory cell infiltration. Symbols represent individual data points with the median as a horizontal line in Fig. 1a, b, d and e. Data are presented as bar graphs with the median and 25–75th percentile of the plasma LRG1 concentrations in Fig. 1f (ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001)
    Human Lrg1 Ab, supplied by Assaypro, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human lrg1 ab/product/Assaypro
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human lrg1 ab - by Bioz Stars, 2024-12
    90/100 stars

    Images

    1) Product Images from "Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis"

    Article Title: Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis

    Journal: BMC Nephrology

    doi: 10.1186/s12882-020-01782-0

    Plasma leucine-rich alpha-2 glycoprotein 1 (LRG1) levels in lupus nephritis (LN) patients and its correlation to indicators. a Plasma LRG1 levels in LN patients and healthy controls. b Differences in plasma concentrations of LRG1 between different patients with different CKD grades. c Plasma levels of LRG1 are positively correlated with serum creatinine (γ = 0.294, P < 0.01). d , e Differences in plasma concentrations of LRG1 between different patients with different SLE activity grade (SLEDAI) and renal SLEDAI (rSLEDAI). f Differences in plasma concentrations of LRG1 between different patients with other different clinical and pathological indicators, 1 and 2 are representative < and ≥ median: 29.0 years for age, 5.0 AI score, 4.0 CI score, 0.4 for complement 3 (C3); female and male for gender; < and ≥ 20 for SLEDAI;<20 and ≥ 20 mm/h for erythrocyte sedimentation rate (ESR); − and + for hematuria, heavy proteinuria, pyuria, casts, double track sign, wireloop sign, endothelial cells hyperplasia and fibrosis; light and heavy for inflammatory cell infiltration. Symbols represent individual data points with the median as a horizontal line in Fig. 1a, b, d and e. Data are presented as bar graphs with the median and 25–75th percentile of the plasma LRG1 concentrations in Fig. 1f (ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001)
    Figure Legend Snippet: Plasma leucine-rich alpha-2 glycoprotein 1 (LRG1) levels in lupus nephritis (LN) patients and its correlation to indicators. a Plasma LRG1 levels in LN patients and healthy controls. b Differences in plasma concentrations of LRG1 between different patients with different CKD grades. c Plasma levels of LRG1 are positively correlated with serum creatinine (γ = 0.294, P < 0.01). d , e Differences in plasma concentrations of LRG1 between different patients with different SLE activity grade (SLEDAI) and renal SLEDAI (rSLEDAI). f Differences in plasma concentrations of LRG1 between different patients with other different clinical and pathological indicators, 1 and 2 are representative < and ≥ median: 29.0 years for age, 5.0 AI score, 4.0 CI score, 0.4 for complement 3 (C3); female and male for gender; < and ≥ 20 for SLEDAI;<20 and ≥ 20 mm/h for erythrocyte sedimentation rate (ESR); − and + for hematuria, heavy proteinuria, pyuria, casts, double track sign, wireloop sign, endothelial cells hyperplasia and fibrosis; light and heavy for inflammatory cell infiltration. Symbols represent individual data points with the median as a horizontal line in Fig. 1a, b, d and e. Data are presented as bar graphs with the median and 25–75th percentile of the plasma LRG1 concentrations in Fig. 1f (ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001)

    Techniques Used: Activity Assay, Sedimentation

    Flow cytometric analysis of leucine-rich alpha-2 glycoprotein 1 (LRG1) expression in peripheral blood leukocytes of LN patients and HC. Quantitative presentations of LRG1+ cells in CD15+ (Neutrophils), CD3-CD 56+ (NK cells), CD14+ (Monocytes), CD3+ (T cells) and CD19+ (B cells) cells for healthy controls and lupus nephritis (LN) patients. n = 3 per group. ns, not significant; * P < 0.05; *** P < 0.001
    Figure Legend Snippet: Flow cytometric analysis of leucine-rich alpha-2 glycoprotein 1 (LRG1) expression in peripheral blood leukocytes of LN patients and HC. Quantitative presentations of LRG1+ cells in CD15+ (Neutrophils), CD3-CD 56+ (NK cells), CD14+ (Monocytes), CD3+ (T cells) and CD19+ (B cells) cells for healthy controls and lupus nephritis (LN) patients. n = 3 per group. ns, not significant; * P < 0.05; *** P < 0.001

    Techniques Used: Expressing

    Leucine-rich alpha-2 glycoprotein 1 (LRG1) was expressed at proximal tubules and several inflammatory cells in kidneys of lupus nephritis (LN) patients. a Continuous kidney paraffin sections of LN patients were co-stained with anti-LRG1 and anti- Lotus tetragonolobus lectin (LTL)/Nacl cotransporter (NCC)/ Dolichos biflorus agglutinin (DBA) antibodies. Representative images of the border areas are shown. Scale bars, 100 μm. b Paraffin sections of LN patients were co-stained with anti-LRG1 and anti-68/11c/3/19 antibodies. Representative images of the border areas are shown. Scale bars, 20 μm
    Figure Legend Snippet: Leucine-rich alpha-2 glycoprotein 1 (LRG1) was expressed at proximal tubules and several inflammatory cells in kidneys of lupus nephritis (LN) patients. a Continuous kidney paraffin sections of LN patients were co-stained with anti-LRG1 and anti- Lotus tetragonolobus lectin (LTL)/Nacl cotransporter (NCC)/ Dolichos biflorus agglutinin (DBA) antibodies. Representative images of the border areas are shown. Scale bars, 100 μm. b Paraffin sections of LN patients were co-stained with anti-LRG1 and anti-68/11c/3/19 antibodies. Representative images of the border areas are shown. Scale bars, 20 μm

    Techniques Used: Staining

    Leucine-rich alpha-2 glycoprotein 1 (LRG1) could be induced by proinflammatory cytokines in HK-2 cell line and its effects on HUVEC cell line. a , b The expressions of LRG1 were analysed by western blot in HK-2 cells stimulated with 20 ng/mL IL-1β, IL-6, TNF-α and INF-γ for 8 h (n = 3). Analyses were performed by Student’s t test. c HUVEC cells stimulated by 500 ng/mL rhLRG1 for 8 h were double stained with FITC-conjugated anti-Annexin Vantibody and PI, followed by flowcytometry analysis for cell apoptosis. d CCK-8 assay was performed to assess cell proliferation in HUVEC cell line. e HUVEC cell line was stimulated by 500 ng/mL rhLRG1 for 24 h. The expression of mRNA was analyzed by real-time RT-PCR and GAPDH was used as an internal control for grayscale analysis. Data are shown as mean ± SEM. c - e analyses were controls groups vs. 500 ng/mL LRG1 stimulating groups performed by Student’s t test. n.s., not significant. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. LRG1: leucine-rich α2-glycoprotein 1; IL: Interleukin; TNF: Tumor necrosis factor; INF: Interferon; CCL: chemokine (C-C motif) ligand; CXCL: Chemokine (C-X-C Motif) Ligand 1
    Figure Legend Snippet: Leucine-rich alpha-2 glycoprotein 1 (LRG1) could be induced by proinflammatory cytokines in HK-2 cell line and its effects on HUVEC cell line. a , b The expressions of LRG1 were analysed by western blot in HK-2 cells stimulated with 20 ng/mL IL-1β, IL-6, TNF-α and INF-γ for 8 h (n = 3). Analyses were performed by Student’s t test. c HUVEC cells stimulated by 500 ng/mL rhLRG1 for 8 h were double stained with FITC-conjugated anti-Annexin Vantibody and PI, followed by flowcytometry analysis for cell apoptosis. d CCK-8 assay was performed to assess cell proliferation in HUVEC cell line. e HUVEC cell line was stimulated by 500 ng/mL rhLRG1 for 24 h. The expression of mRNA was analyzed by real-time RT-PCR and GAPDH was used as an internal control for grayscale analysis. Data are shown as mean ± SEM. c - e analyses were controls groups vs. 500 ng/mL LRG1 stimulating groups performed by Student’s t test. n.s., not significant. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. LRG1: leucine-rich α2-glycoprotein 1; IL: Interleukin; TNF: Tumor necrosis factor; INF: Interferon; CCL: chemokine (C-C motif) ligand; CXCL: Chemokine (C-X-C Motif) Ligand 1

    Techniques Used: Western Blot, Staining, CCK-8 Assay, Expressing, Quantitative RT-PCR

    Renal cortical expression of leucine-rich alpha-2 glycoprotein 1 (LRG1) in human kidney biopsies. Representative photomicrographs of LRG1 staining in human renal cortical tissue from normal subjects ( a and b ), lupus nephritis (LN) patients ( c and d ). Hematoxylin stain; original magnification, × 200 (A and C, Scale bars, 50 μm); × 400 ( b and d , Scale bars, 20 μm)
    Figure Legend Snippet: Renal cortical expression of leucine-rich alpha-2 glycoprotein 1 (LRG1) in human kidney biopsies. Representative photomicrographs of LRG1 staining in human renal cortical tissue from normal subjects ( a and b ), lupus nephritis (LN) patients ( c and d ). Hematoxylin stain; original magnification, × 200 (A and C, Scale bars, 50 μm); × 400 ( b and d , Scale bars, 20 μm)

    Techniques Used: Expressing, Staining



    Similar Products

    human lrg1 ab  (Assaypro)
    90
    Assaypro human lrg1 ab
    Plasma leucine-rich alpha-2 glycoprotein 1 <t>(LRG1)</t> levels in lupus nephritis (LN) patients and its correlation to indicators. a Plasma LRG1 levels in LN patients and healthy controls. b Differences in plasma concentrations of LRG1 between different patients with different CKD grades. c Plasma levels of LRG1 are positively correlated with serum creatinine (γ = 0.294, P < 0.01). d , e Differences in plasma concentrations of LRG1 between different patients with different SLE activity grade (SLEDAI) and renal SLEDAI (rSLEDAI). f Differences in plasma concentrations of LRG1 between different patients with other different clinical and pathological indicators, 1 and 2 are representative < and ≥ median: 29.0 years for age, 5.0 AI score, 4.0 CI score, 0.4 for complement 3 (C3); female and male for gender; < and ≥ 20 for SLEDAI;<20 and ≥ 20 mm/h for erythrocyte sedimentation rate (ESR); − and + for hematuria, heavy proteinuria, pyuria, casts, double track sign, wireloop sign, endothelial cells hyperplasia and fibrosis; light and heavy for inflammatory cell infiltration. Symbols represent individual data points with the median as a horizontal line in Fig. 1a, b, d and e. Data are presented as bar graphs with the median and 25–75th percentile of the plasma LRG1 concentrations in Fig. 1f (ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001)
    Human Lrg1 Ab, supplied by Assaypro, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human lrg1 ab/product/Assaypro
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human lrg1 ab - by Bioz Stars, 2024-12
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Plasma leucine-rich alpha-2 glycoprotein 1 (LRG1) levels in lupus nephritis (LN) patients and its correlation to indicators. a Plasma LRG1 levels in LN patients and healthy controls. b Differences in plasma concentrations of LRG1 between different patients with different CKD grades. c Plasma levels of LRG1 are positively correlated with serum creatinine (γ = 0.294, P < 0.01). d , e Differences in plasma concentrations of LRG1 between different patients with different SLE activity grade (SLEDAI) and renal SLEDAI (rSLEDAI). f Differences in plasma concentrations of LRG1 between different patients with other different clinical and pathological indicators, 1 and 2 are representative < and ≥ median: 29.0 years for age, 5.0 AI score, 4.0 CI score, 0.4 for complement 3 (C3); female and male for gender; < and ≥ 20 for SLEDAI;<20 and ≥ 20 mm/h for erythrocyte sedimentation rate (ESR); − and + for hematuria, heavy proteinuria, pyuria, casts, double track sign, wireloop sign, endothelial cells hyperplasia and fibrosis; light and heavy for inflammatory cell infiltration. Symbols represent individual data points with the median as a horizontal line in Fig. 1a, b, d and e. Data are presented as bar graphs with the median and 25–75th percentile of the plasma LRG1 concentrations in Fig. 1f (ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001)

    Journal: BMC Nephrology

    Article Title: Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis

    doi: 10.1186/s12882-020-01782-0

    Figure Lengend Snippet: Plasma leucine-rich alpha-2 glycoprotein 1 (LRG1) levels in lupus nephritis (LN) patients and its correlation to indicators. a Plasma LRG1 levels in LN patients and healthy controls. b Differences in plasma concentrations of LRG1 between different patients with different CKD grades. c Plasma levels of LRG1 are positively correlated with serum creatinine (γ = 0.294, P < 0.01). d , e Differences in plasma concentrations of LRG1 between different patients with different SLE activity grade (SLEDAI) and renal SLEDAI (rSLEDAI). f Differences in plasma concentrations of LRG1 between different patients with other different clinical and pathological indicators, 1 and 2 are representative < and ≥ median: 29.0 years for age, 5.0 AI score, 4.0 CI score, 0.4 for complement 3 (C3); female and male for gender; < and ≥ 20 for SLEDAI;<20 and ≥ 20 mm/h for erythrocyte sedimentation rate (ESR); − and + for hematuria, heavy proteinuria, pyuria, casts, double track sign, wireloop sign, endothelial cells hyperplasia and fibrosis; light and heavy for inflammatory cell infiltration. Symbols represent individual data points with the median as a horizontal line in Fig. 1a, b, d and e. Data are presented as bar graphs with the median and 25–75th percentile of the plasma LRG1 concentrations in Fig. 1f (ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001)

    Article Snippet: In addition, we used FITC-conjugated anti–human LRG1 Ab from ASSAYPRO.

    Techniques: Activity Assay, Sedimentation

    Flow cytometric analysis of leucine-rich alpha-2 glycoprotein 1 (LRG1) expression in peripheral blood leukocytes of LN patients and HC. Quantitative presentations of LRG1+ cells in CD15+ (Neutrophils), CD3-CD 56+ (NK cells), CD14+ (Monocytes), CD3+ (T cells) and CD19+ (B cells) cells for healthy controls and lupus nephritis (LN) patients. n = 3 per group. ns, not significant; * P < 0.05; *** P < 0.001

    Journal: BMC Nephrology

    Article Title: Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis

    doi: 10.1186/s12882-020-01782-0

    Figure Lengend Snippet: Flow cytometric analysis of leucine-rich alpha-2 glycoprotein 1 (LRG1) expression in peripheral blood leukocytes of LN patients and HC. Quantitative presentations of LRG1+ cells in CD15+ (Neutrophils), CD3-CD 56+ (NK cells), CD14+ (Monocytes), CD3+ (T cells) and CD19+ (B cells) cells for healthy controls and lupus nephritis (LN) patients. n = 3 per group. ns, not significant; * P < 0.05; *** P < 0.001

    Article Snippet: In addition, we used FITC-conjugated anti–human LRG1 Ab from ASSAYPRO.

    Techniques: Expressing

    Leucine-rich alpha-2 glycoprotein 1 (LRG1) was expressed at proximal tubules and several inflammatory cells in kidneys of lupus nephritis (LN) patients. a Continuous kidney paraffin sections of LN patients were co-stained with anti-LRG1 and anti- Lotus tetragonolobus lectin (LTL)/Nacl cotransporter (NCC)/ Dolichos biflorus agglutinin (DBA) antibodies. Representative images of the border areas are shown. Scale bars, 100 μm. b Paraffin sections of LN patients were co-stained with anti-LRG1 and anti-68/11c/3/19 antibodies. Representative images of the border areas are shown. Scale bars, 20 μm

    Journal: BMC Nephrology

    Article Title: Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis

    doi: 10.1186/s12882-020-01782-0

    Figure Lengend Snippet: Leucine-rich alpha-2 glycoprotein 1 (LRG1) was expressed at proximal tubules and several inflammatory cells in kidneys of lupus nephritis (LN) patients. a Continuous kidney paraffin sections of LN patients were co-stained with anti-LRG1 and anti- Lotus tetragonolobus lectin (LTL)/Nacl cotransporter (NCC)/ Dolichos biflorus agglutinin (DBA) antibodies. Representative images of the border areas are shown. Scale bars, 100 μm. b Paraffin sections of LN patients were co-stained with anti-LRG1 and anti-68/11c/3/19 antibodies. Representative images of the border areas are shown. Scale bars, 20 μm

    Article Snippet: In addition, we used FITC-conjugated anti–human LRG1 Ab from ASSAYPRO.

    Techniques: Staining

    Leucine-rich alpha-2 glycoprotein 1 (LRG1) could be induced by proinflammatory cytokines in HK-2 cell line and its effects on HUVEC cell line. a , b The expressions of LRG1 were analysed by western blot in HK-2 cells stimulated with 20 ng/mL IL-1β, IL-6, TNF-α and INF-γ for 8 h (n = 3). Analyses were performed by Student’s t test. c HUVEC cells stimulated by 500 ng/mL rhLRG1 for 8 h were double stained with FITC-conjugated anti-Annexin Vantibody and PI, followed by flowcytometry analysis for cell apoptosis. d CCK-8 assay was performed to assess cell proliferation in HUVEC cell line. e HUVEC cell line was stimulated by 500 ng/mL rhLRG1 for 24 h. The expression of mRNA was analyzed by real-time RT-PCR and GAPDH was used as an internal control for grayscale analysis. Data are shown as mean ± SEM. c - e analyses were controls groups vs. 500 ng/mL LRG1 stimulating groups performed by Student’s t test. n.s., not significant. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. LRG1: leucine-rich α2-glycoprotein 1; IL: Interleukin; TNF: Tumor necrosis factor; INF: Interferon; CCL: chemokine (C-C motif) ligand; CXCL: Chemokine (C-X-C Motif) Ligand 1

    Journal: BMC Nephrology

    Article Title: Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis

    doi: 10.1186/s12882-020-01782-0

    Figure Lengend Snippet: Leucine-rich alpha-2 glycoprotein 1 (LRG1) could be induced by proinflammatory cytokines in HK-2 cell line and its effects on HUVEC cell line. a , b The expressions of LRG1 were analysed by western blot in HK-2 cells stimulated with 20 ng/mL IL-1β, IL-6, TNF-α and INF-γ for 8 h (n = 3). Analyses were performed by Student’s t test. c HUVEC cells stimulated by 500 ng/mL rhLRG1 for 8 h were double stained with FITC-conjugated anti-Annexin Vantibody and PI, followed by flowcytometry analysis for cell apoptosis. d CCK-8 assay was performed to assess cell proliferation in HUVEC cell line. e HUVEC cell line was stimulated by 500 ng/mL rhLRG1 for 24 h. The expression of mRNA was analyzed by real-time RT-PCR and GAPDH was used as an internal control for grayscale analysis. Data are shown as mean ± SEM. c - e analyses were controls groups vs. 500 ng/mL LRG1 stimulating groups performed by Student’s t test. n.s., not significant. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. LRG1: leucine-rich α2-glycoprotein 1; IL: Interleukin; TNF: Tumor necrosis factor; INF: Interferon; CCL: chemokine (C-C motif) ligand; CXCL: Chemokine (C-X-C Motif) Ligand 1

    Article Snippet: In addition, we used FITC-conjugated anti–human LRG1 Ab from ASSAYPRO.

    Techniques: Western Blot, Staining, CCK-8 Assay, Expressing, Quantitative RT-PCR

    Renal cortical expression of leucine-rich alpha-2 glycoprotein 1 (LRG1) in human kidney biopsies. Representative photomicrographs of LRG1 staining in human renal cortical tissue from normal subjects ( a and b ), lupus nephritis (LN) patients ( c and d ). Hematoxylin stain; original magnification, × 200 (A and C, Scale bars, 50 μm); × 400 ( b and d , Scale bars, 20 μm)

    Journal: BMC Nephrology

    Article Title: Leucine-rich α2-glycoprotein-1 upregulation in plasma and kidney of patients with lupus nephritis

    doi: 10.1186/s12882-020-01782-0

    Figure Lengend Snippet: Renal cortical expression of leucine-rich alpha-2 glycoprotein 1 (LRG1) in human kidney biopsies. Representative photomicrographs of LRG1 staining in human renal cortical tissue from normal subjects ( a and b ), lupus nephritis (LN) patients ( c and d ). Hematoxylin stain; original magnification, × 200 (A and C, Scale bars, 50 μm); × 400 ( b and d , Scale bars, 20 μm)

    Article Snippet: In addition, we used FITC-conjugated anti–human LRG1 Ab from ASSAYPRO.

    Techniques: Expressing, Staining